Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.38 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.35 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL335350 | 0.83 | ALDH1A1 (0.50) | THRBALDH1A1TP53HSD17B10NPC1 | |
| SCHEMBL13736275 | 0.81 | NNMT (0.44) | THRBALDH1A1TP53HSD17B10NPC1 | |
| SCHEMBL10588737 | 0.79 | TP53 (0.38) | THRBALDH1A1TP53HSD17B10NPC1 | |
| SCHEMBL2970976 | 0.78 | MAPK1 (0.50) | THRBALDH1A1TP53HSD17B10NPC1 | |
| Acetonitrile SCHEMBL27812716 | 0.75 | ALDH1A1 (0.43) | THRBALDH1A1TP53HSD17B10NPC1 | |
| SCHEMBL14480244 | 0.74 | KCNJ1 (0.42) | ALDH1A1TP53MAPTP4HTMKCNJ1 | |
| SCHEMBL27773731 | 0.74 | MAPT (0.44) | THRBALDH1A1TP53HSD17B10NPC1 | |
| SCHEMBL650818 | 0.74 | HTT (0.60) | THRBALDH1A1TP53HSD17B10NPC1 | |
| SCHEMBL5189305 | 0.74 | HPGDS (0.43) | THRBALDH1A1TP53HSD17B10NPC1 | |
| SCHEMBL10588269 | 0.72 | GAA (0.48) | ALDH1A1NPC1MAPTMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| US-9193749-B2 | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors | FORUM PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20140011988-A1 | Dibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2014-01-09 | — | — | US | disclosed |
| US-8399452-B2 | Anticancer agents; antiproliferative agenst; antiprotozoa agents | METHYLGENE INC. (CA) | 2013-03-19 | — | — | US | disclosed |
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-08-11 | — | — | US | disclosed |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| EP-0325131-A2 | Pyrimidine derivatives as performance stimulating agents | BAYER AG (DE) | 1989-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC2 | THRB 3157/4885ALDH1A1 1127/4885TP53 1296/4885 |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC11 | THRB 3565/4885ALDH1A1 540/4885TP53 2238/4885 |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC2 | THRB 3157/4885ALDH1A1 1127/4885TP53 1296/4885 |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | HDAC5, KAT2A, HDAC1 | THRB 2982/4885ALDH1A1 1086/4885TP53 1186/4885 |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | HDAC1, HDAC2, HDAC4 | THRB 2474/4885ALDH1A1 235/4885TP53 3710/4885 |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC11 | THRB 3565/4885ALDH1A1 540/4885TP53 2238/4885 |
| US-20140011988-A1 | Dibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | HDAC1, HDAC2, HDAC4 | THRB 2474/4885ALDH1A1 235/4885TP53 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.